ClinicalTrials.gg
RecruitingNCT05752149STELLARUpdated Sep 14, 2026

Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial

A Phase 2 interventional study of CRGD-ZW800-1 in Squamous Cell Carcinoma of the Larynx and Squamous Cell Carcinoma of the Hypopharynx, sponsored by Erasmus Medical Center. Recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Erasmus Medical Center · Phase 2, Interventional, and Diagnostic

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 75 studies in Squamous Cell Carcinoma of Head and Neck with a site in Netherlands — 16 open to participants now, 28 under way, 6 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Netherlands.

Planned enrollment
51st of 63
27 · median 160
Started
2026
with 1 other
Phase 2
17 of 75
2 open now
Primary completion
2028-03
later than 19 of 27 live
Registered
57th of 75
by date
Lead sponsor
5 of 75
Erasmus Medical Center

Among the 75 studies in Squamous Cell Carcinoma of Head and Neck with a site in Netherlands, this one is the 51st largest by planned enrollment of the 63 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 in phase 2, reaches primary completion later than 19 of the 27 other live ones, and was the 57th registered.

Squamous Cell Carcinoma of Head and Neck

2,020 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

16 of the 75 studies in Squamous Cell Carcinoma of Head and Neck with a site in Netherlands are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Squamous Cell Carcinoma of Head and Neck with a site in Netherlands, or all of them as a file.
02

Study summary

This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.

Read the detailed description

This is a two staged clinical trial to investigate intraoperative fluorescence imaging in patientsundergoing TLE. WP-I is a dose finding study in which 2 doses will be tested with a possibility of a third dosing group. Every dosing cohort comprises 3 patients. After WP-I, an interim analysis will be performed to decide the optimal dose.

The optimal dose will be based on the TBR and the performance in detecting the most close margin (i.e. 'the sentinel margin'). A TBR of at least 1.5 is required for the optimal dose. If a positive margin is missed with fluorescence imaging, the concerned dose will be defined as suboptimal.

WP-II is an extension cohort of the optimal dose cohort selected in WP-I. WP-II will comprise of 18 patients.

The endpoints for WP-II are:

  • the rate of tumor free resection margins based on the current golden standard;
  • Sensitivity, specificity and positive predictive value of FLI;
  • The intraoperative change in surgical management based on FLI;
  • FLI of excised cervical lymph nodes;
  • Influence of previous radiotherapy on the FLI performance;
  • Adverse events and toxicity after intravenous injection with cRGD-ZW800-1;
03

Conditions studied

  • Squamous Cell Carcinoma of the Larynx
  • Squamous Cell Carcinoma of the Hypopharynx

Keywords

  • Tumour specific fluorescence imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with -proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE;
  • ≥ 18 years of age;
  • Written must be obtained;
  • Sufficient knowledge of the Dutch language to understand the informed consent form;

Exclusion criteria

Exclusion Criteria:

  • History of a allergy or anaphylactic reactions to any of the components of the agent;
  • Other synchronous proven currently active, except for adequately treated in situ carcinoma of cervix and basal, squamous cell skin carcinoma, or other head- and neck squamous cell cancer;
  • Patients pregnant or breastfeeding;
  • Patients with renal insufficiency (defined as \< 60);
  • Patients with previous kidney transplantation or a solitary functioning kidney;
  • Patients using medications that may significantly impair renal function (i.e. NSAIDs, particularly COX-2 inhibitors), that cannot be paused during the course of the study;
  • Patients with of 4 or higher;
  • Patients with measured of 500 ms or higher at screening;
  • Patients with laboratory abnormalities defined as:

    • , Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the or;
    • Total above 3 times the ULN or;
    • count below 100 x 109/L or;
    • below 4 mmol/L (females) or below 5 mmol/l (males).
  • Immuno-compromised patients who do not have the ability to respond normally to an infection due to an impaired or weakened immune system, caused by either a preexisting disease or concomitant medications;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Care provider)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    0.05 mg/kg cRGD-ZW800-1

    n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery

    Drug: CRGD-ZW800-1

  • Experimental
    0.025 mg/kg cRGD-ZW800-1

    n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery

    Drug: CRGD-ZW800-1

  • Experimental
    0.01 mg/kg cRGD-ZW800-1

    n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.

    Drug: CRGD-ZW800-1

  • Experimental
    Expansion Cohort

    n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.

    Drug: CRGD-ZW800-1

Interventions

  • DrugCRGD-ZW800-1

    Intravenous administration of study drug at lesat 2h prior to surgery

06

What researchers measure

Primary outcomes

  1. WP-I: the optimal dose of cRGD-ZW800-1 for FLI of laryngeal and hypopharyngeal cancer

    Based on the tumor-to-background ratio (TBR) on breadloaves. Higher TBRs indicate a better outcome

    Time frame: Up to 48 hours after administration (Depending on pathology grossing)

  2. WP-II: the rate of clear tumor resection margins

    Time frame: Through histopathology, up to max 4 weeks post-op

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Uponr reasonable reasonable request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 24 months is below that.

Counting every sponsor, half of 365 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 2, 2023
StartActual
Mar 31, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05752149
Responsible party
Stijn Keereweer (Otorhinolaryngologist, Head and Neck Surgeon, MD, PhD, Erasmus Medical Center) — Principal investigator
First posted
Mar 2, 2023
Start date
Mar 31, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Sep 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion